2. Cell Cycle/DNA Damage
  3. Deubiquitinase
  4. P6620

P6620 is an orally active USP7 inhibitor. P6620 specifically binds to USP7 and disrupts its interaction with LRRC41. P6620 exhibits anticancer activity against hepatocellular carcinoma. P6620 enhances the antitumor effect of Lenvatinib (HY-10981) in xenograft mouse models. P6620 can be used for the research of hepatocellular carcinoma.

For research use only. We do not sell to patients.

P6620

P6620 Chemical Structure

CAS No. : 2009272-81-3

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

P6620 Related Antibodies

Top Publications Citing Use of Products

View All Deubiquitinase Isoform Specific Products:

View All Isoforms
USP1 USP2 USP4 USP7 USP8 USP10 USP21 USP30 UCHL1 USP11 USP15 USP28 USP25

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

P6620 is an orally active USP7 inhibitor. P6620 specifically binds to USP7 and disrupts its interaction with LRRC41. P6620 exhibits anticancer activity against hepatocellular carcinoma. P6620 enhances the antitumor effect of Lenvatinib (HY-10981) in xenograft mouse models. P6620 can be used for the research of hepatocellular carcinoma[1].

IC50 & Target[1]

USP7

 

In Vitro

P6620 (0-2.0 μM; 72 h) potently inhibits the viability of MHCC97H and HepG2 human hepatocellular carcinoma cells with an IC50 of 11.31 μM, and 10 μM or 20 μM P6620 significantly reduces cell viability after 72 h of incubation[1].
P6620 (5-20 μM; 48 h) dose-dependently decreases USP7 and LRRC41 protein levels in MHCC97H and HepG2 human hepatocellular carcinoma cells after 48 h of incubation, and MG132 reverses the P6620-induced reduction in LRRC41 protein[1].
P6620 (10-20 μM; 48 h) significantly inhibits the invasion and migration of MHCC97H and HepG2 human hepatocellular carcinoma cells after 48 h of incubation[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

P6620 Related Antibodies

Cell Viability Assay[1]

Cell Line: human hepatocellular carcinoma MHCC97H, HepG2 cells
Concentration: 0-2.0 μM (viability measurement); 10, 20 μM (24-72 h incubation)
Incubation Time: 24-72 h (10, 20 μM treatment)
Result: Reduced HCC cell viability in a concentration-dependent manner, with an IC50 of 11.31 μM.
Significantly decreased the viability of MHCC97H and HepG2 cells compared with untreated controls when treated with 10 μM or 20 μM.

Western Blot Analysis[1]

Cell Line: human hepatocellular carcinoma MHCC97H, HepG2 cells
Concentration: 5-20 μM (48 h incubation); 10 μM (48 h incubation, followed by 8 h incubation with 10 μM MG132)
Incubation Time: 48 h (5-20 μM treatment); 48 h + 8 h (10 μM P6620 + 10 μM MG132 treatment)
Result: Dose-dependently reduced USP7 and LRRC41 protein levels in MHCC97H and HepG2 cells when treated with 5, 10, or 20 μM for 48 h.
In Vivo

P6620 (20 mg/kg; p.o.; 5 times per week; for 14 consecutive days) significantly reduces tumor weight in a hepatocellular carcinoma xenograft mouse model, and its efficacy is enhanced when used in combination with Lenvatinib (HY-10981)[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: nude mice (male, 4 weeks old, subcutaneously inoculated with MHCC97H cells)[1]
Dosage: 20 mg/kg
Administration: p.o.; 5 times weekly; 14 days
Result: Significantly reduced tumour weight compared with the control group.
Significantly reduced Ki67 and USP7 expression in tumour tissues relative to controls.
Molecular Weight

306.36

Formula

C19H18N2O2
CAS No.
SMILES

OC1=CC=C(C2=C(CC)C(C3=CC=C(O)C=C3)=C(N)N=C2)C=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

P6620 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

P66202009272-81-3P 6620P-6620DeubiquitinaseDUBsxenograft mouse modelsLRRC41lenvatinibhepatocellular carcinomaHepG2MG132ubiquitin-dependent degradationUSP7MHCC97HKi67Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
P6620
Cat. No.:
HY-183078
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.